TY - JOUR
T1 - The Efficacy of Human Papillomavirus Vaccination as an Adjuvant Therapy in Recurrent Respiratory Papillomatosis
AU - Ponduri, Anusha
AU - Azmy, Monica C.
AU - Axler, Eden
AU - Lin, Juan
AU - Schwartz, Rachel
AU - Chiril?, Magdalena
AU - Dikkers, Frederik G.
AU - Yang, Christina J.
AU - Mehta, Vikas
AU - Gangar, Mona
N1 - Publisher Copyright: © 2023 The American Laryngological, Rhinological and Otological Society, Inc.
PY - 2023/9
Y1 - 2023/9
N2 - Objective: To characterize the efficacy of human papillomavirus (HPV) vaccination as an adjuvant therapy in recurrent respiratory papillomatosis (RRP). Data Sources: PubMed, Embase, Cochrane, Google Scholar, ClinicalTrials.gov, and Web of Science databases were queried for articles published before April 2021. Review Methods: All retrieved studies (n = 870) were independently analyzed by two reviewers according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement using predefined inclusion and exclusion criteria. 13 studies met inclusion criteria. A random-effects meta-analysis was performed to study intersurgical interval (ISI) and number of surgical procedures per year before and after vaccination. Results: The systematic review included 13 studies, comprising 243 patients. All studies utilized the Gardasil® quadrivalent vaccine, and one study (Yiu et al. 2019) utilized both the quadrivalent and Gardasil® 9-valent vaccines. Our meta-analysis included 62 patients with ISI data across 4 studies, and 111 patients with data on the number of surgical procedures per month across 7 studies. The mean number of surgical procedures decreased by 4.43 per year after vaccination (95% CI, −7.48 to −1.37). Mean ISI increased after vaccination, with a mean difference of 15.73 months (95% CI, 1.46–29.99). Two studies reported on HPV sero-conversion, with HPV seropositivity of 100% prior to vaccination and 25.93% after vaccination. Conclusion: The addition of HPV vaccination was associated with an increase in time between surgeries and reduction in the number of surgical procedures required. HPV vaccination may be a beneficial adjuvant treatment for RRP. Level of Evidence: NA Laryngoscope, 133:2046–2054, 2023.
AB - Objective: To characterize the efficacy of human papillomavirus (HPV) vaccination as an adjuvant therapy in recurrent respiratory papillomatosis (RRP). Data Sources: PubMed, Embase, Cochrane, Google Scholar, ClinicalTrials.gov, and Web of Science databases were queried for articles published before April 2021. Review Methods: All retrieved studies (n = 870) were independently analyzed by two reviewers according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement using predefined inclusion and exclusion criteria. 13 studies met inclusion criteria. A random-effects meta-analysis was performed to study intersurgical interval (ISI) and number of surgical procedures per year before and after vaccination. Results: The systematic review included 13 studies, comprising 243 patients. All studies utilized the Gardasil® quadrivalent vaccine, and one study (Yiu et al. 2019) utilized both the quadrivalent and Gardasil® 9-valent vaccines. Our meta-analysis included 62 patients with ISI data across 4 studies, and 111 patients with data on the number of surgical procedures per month across 7 studies. The mean number of surgical procedures decreased by 4.43 per year after vaccination (95% CI, −7.48 to −1.37). Mean ISI increased after vaccination, with a mean difference of 15.73 months (95% CI, 1.46–29.99). Two studies reported on HPV sero-conversion, with HPV seropositivity of 100% prior to vaccination and 25.93% after vaccination. Conclusion: The addition of HPV vaccination was associated with an increase in time between surgeries and reduction in the number of surgical procedures required. HPV vaccination may be a beneficial adjuvant treatment for RRP. Level of Evidence: NA Laryngoscope, 133:2046–2054, 2023.
KW - human papillomavirus recombinant vaccine quadrivalent
KW - laryngeal papilloma
KW - papillomavirus vaccines
KW - recurrent
KW - recurrent respiratory papillomatosis
KW - respiratory papillomatosis
KW - types 6, 11, 16, 18
UR - http://www.scopus.com/inward/record.url?scp=85146447744&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/lary.30560
DO - https://doi.org/10.1002/lary.30560
M3 - Review article
C2 - 36651338
SN - 0023-852X
VL - 133
SP - 2046
EP - 2054
JO - Laryngoscope
JF - Laryngoscope
IS - 9
ER -